Abstract
The increasing occurrence of antibiotic-resistant pathogens influences the treatment approach to respiratory tract infections and complicates the selection of the anti-infectious drug and dosing regimen. Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics both influence dosing regimens of antimicrobials. PK (the overall disposition of the drug in the body) is reflected by the serum concentration profile over time. PD can be characterized by the susceptibility of the pathogen to the drug, determined by measuring the minimum inhibitory concentration (MIC), which is a potency of the drug. There is an increasing need to identify new therapeutic approaches which improve the chance to reduce the morbidity and obtain successful outcomes. So far, antibiotic dosing has been focused on PK concepts, mainly the penetration of drug into sites of infection and its elimination half-life. Recently, a new appealing approach integrating PK and PD features has been suggested to implement optimal antibiotic dosing regimens, since several studies in animals and humans found a striking correlation between bacteriological outcome and specific PK/PD indices. It appears it would lead to better results not only in terms of clinical and bacteriological cure but also in the whole patient care.
Keywords: Antibiotics, MIC, pharmacokinetic/pharmacodynamic indices, respiratory tract infection
Current Respiratory Medicine Reviews
Title: Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Volume: 2 Issue: 1
Author(s): D. Soy, J. R. Badia and A. Torres
Affiliation:
Keywords: Antibiotics, MIC, pharmacokinetic/pharmacodynamic indices, respiratory tract infection
Abstract: The increasing occurrence of antibiotic-resistant pathogens influences the treatment approach to respiratory tract infections and complicates the selection of the anti-infectious drug and dosing regimen. Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics both influence dosing regimens of antimicrobials. PK (the overall disposition of the drug in the body) is reflected by the serum concentration profile over time. PD can be characterized by the susceptibility of the pathogen to the drug, determined by measuring the minimum inhibitory concentration (MIC), which is a potency of the drug. There is an increasing need to identify new therapeutic approaches which improve the chance to reduce the morbidity and obtain successful outcomes. So far, antibiotic dosing has been focused on PK concepts, mainly the penetration of drug into sites of infection and its elimination half-life. Recently, a new appealing approach integrating PK and PD features has been suggested to implement optimal antibiotic dosing regimens, since several studies in animals and humans found a striking correlation between bacteriological outcome and specific PK/PD indices. It appears it would lead to better results not only in terms of clinical and bacteriological cure but also in the whole patient care.
Export Options
About this article
Cite this article as:
Soy D., Badia R. J. and Torres A., Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era, Current Respiratory Medicine Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339806775486218
DOI https://dx.doi.org/10.2174/157339806775486218 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peculiarities of the Clinical Course of Oxidative Protein and Lipid Modification in Children with Acute Rheumatic Fever
Endocrine, Metabolic & Immune Disorders - Drug Targets Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Candida parapsilosis Secreted Lipase as an Important Virulence Factor
Current Protein & Peptide Science Long-term Results After Transcatheter Aortic Valve Implantation: What do we Know Today?
Current Cardiology Reviews Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
Current Pharmaceutical Biotechnology Can Statins Prevent Progression of Degenerated Aortic Valve Stenosis?
Vascular Disease Prevention (Discontinued) Structural Insights into Chitinolytic Enzymes and Inhibition Mechanisms of Selective Inhibitors
Current Pharmaceutical Design New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Complementary Therapies in Inflammatory Bowel Diseases
Current Drug Targets The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Antibiotic Use in Children - Off-Label Use
Current Drug Targets Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
Current Drug Abuse Reviews Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology